Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.

{"article_title":"Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.","author":"Adams KF Jr, Giblin EM, Pearce N, Patterson JH","journal_title":"Pharmacotherapy","issn":"1875-9114","isbn":"","publication_date":"2017 Jun","volume":"37","issue":"6","first_page":"645","page_count":"","accession_number":"28394465","doi":"10.1002\/phar.1934","publisher":"Wiley-Blackwell","doctype":"Journal Article","subjects":"Aminobutyrates therapeutic use; Angiotensin Receptor Antagonists therapeutic use; Benzazepines therapeutic use; Heart Failure drug therapy; Practice Guidelines as Topic standards; Tetrazoles therapeutic use; Biphenyl Compounds; Drug Combinations; Heart Failure diagnosis; Heart Failure physiopathology; Humans; Ivabradine; Treatment Outcome; Valsartan","interest_area":["Cardiology"," Emergency Medicine"],"abstract":"Heart failure is well recognized as a major public health concern not only due to severe and frequent adverse health outcomes but also related to the major financial burden this syndrome presents with advancing age in Western societies. Despite the dire need for more efficacious therapies and better application of existing advances, treatment gaps persist, and outcomes in heart failure remain poor, with continually high mortality and morbidity. Treatment guidelines provide one strategy for advancing quality of care in patients with heart failure. This approach, with well-known potential strengths and weaknesses, has both adherents and detractors. Heart failure treatment guidelines have been in sharp focus recently due to updates that address the United States Food and Drug Administration (FDA) approval in 2015 of two new pharmacologic therapies for heart failure with reduced ejection fraction: sacubitril-valsartan and ivabradine. Our commentary will revisit issues in guideline methodology and discuss these in the context of the updates addressing the FDA approval of new pharmacologic agents for heart failure with reduced ejection fraction. \ufffd 2017 Pharmacotherapy Publications, Inc.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=28394465&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Adams KF Jr, Giblin EM, Pearce N, Patterson JH","Journal_Info":"Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8111305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1875-9114 (Electronic) Linking ISSN: 02770008 NLM ISO Abbreviation: Pharmacotherapy Subsets: MEDLINE","Publication_Type":"Journal Article; Review","Published_Date":"2017-06-01","Source":"Pharmacotherapy [Pharmacotherapy] 2017 Jun; Vol. 37 (6), pp. 645-656. Date of Electronic Publication: 2017 Jun 09.","Languages":"English","Electronic_ISSN":"1875-9114","MeSH_Terms":"Aminobutyrates\/*therapeutic use , Angiotensin Receptor Antagonists\/*therapeutic use , Benzazepines\/*therapeutic use , Heart Failure\/*drug therapy , Practice Guidelines as Topic\/*standards , Tetrazoles\/*therapeutic use, Biphenyl Compounds ; Drug Combinations ; Heart Failure\/diagnosis ; Heart Failure\/physiopathology ; Humans ; Ivabradine ; Treatment Outcome ; Valsartan","Subjects":"Biphenyl Compounds, Drug Combinations, Heart Failure diagnosis, Heart Failure physiopathology, Humans, Ivabradine, Treatment Outcome, Valsartan, Aminobutyrates therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Benzazepines therapeutic use, Heart Failure drug therapy, Practice Guidelines as Topic standards, Tetrazoles therapeutic use","Title_Abbreviations":"Pharmacotherapy","Volume":"37"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"28394465","RelevancyScore":"808","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"808.287353515625"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=28394465&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=28394465&authtype=shib&custid=ns346513&group=main&profile=eds"}